387 related articles for article (PubMed ID: 31715456)
1. Google searches and medical publication trends since the 2014 US Food and Drug Administration position on power morcellation: Do these translate into patient awareness?
Liou NS; Mallick R; Aref-Adib M; Odejinmi F
Eur J Obstet Gynecol Reprod Biol; 2019 Dec; 243():168-172. PubMed ID: 31715456
[TBL] [Abstract][Full Text] [Related]
2. Laparoscopic myomectomy and morcellation: A review of techniques, outcomes, and practice guidelines.
Glaser LM; Friedman J; Tsai S; Chaudhari A; Milad M
Best Pract Res Clin Obstet Gynaecol; 2018 Jan; 46():99-112. PubMed ID: 29078975
[TBL] [Abstract][Full Text] [Related]
3. No. 371-Morcellation During Gynaecologic Surgery: Its Uses, Complications, and Risks of Unsuspected Malignancy.
Murji A; Scott S; Singh SS; Bougie O; Leyland N; Laberge PY; Vilos GA
J Obstet Gynaecol Can; 2019 Jan; 41(1):116-126. PubMed ID: 30580824
[TBL] [Abstract][Full Text] [Related]
4. Morcellation of occulted sarcomas during laparoscopic myomectomy and hysterectomy for patients with large fibroid uterus.
Tinelli A; Farghaly SA
Minerva Ginecol; 2018 Feb; 70(1):84-88. PubMed ID: 28975775
[TBL] [Abstract][Full Text] [Related]
5. What is the Future of Open Intraperitoneal Power-Morcellation of Fibroids?
Parker WH; Pritts EA; Olive DL
Clin Obstet Gynecol; 2016 Mar; 59(1):73-84. PubMed ID: 26670834
[TBL] [Abstract][Full Text] [Related]
6. Public Awareness of Uterine Power Morcellation Through US Food and Drug Administration Communications: Analysis of Google Trends Search Term Patterns.
Wood LN; Jamnagerwalla J; Markowitz MA; Thum DJ; McCarty P; Medendorp AR; Raz S; Kim JH
JMIR Public Health Surveill; 2018 Apr; 4(2):e47. PubMed ID: 29699965
[TBL] [Abstract][Full Text] [Related]
7. Occult Leiomyosarcomas in a Canadian Province: A Retrospective Cohort Study.
Wu CQ; Woo LY; Giede KC; Thiel J; Karreman E; Rattray DD
J Obstet Gynaecol Can; 2019 Jan; 41(1):46-51. PubMed ID: 30341020
[TBL] [Abstract][Full Text] [Related]
8. Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation.
Harris JA; Swenson CW; Uppal S; Kamdar N; Mahnert N; As-Sanie S; Morgan DM
Am J Obstet Gynecol; 2016 Jan; 214(1):98.e1-98.e13. PubMed ID: 26314519
[TBL] [Abstract][Full Text] [Related]
9. Risk of Undetected Cancer at the Time of Laparoscopic Supracervical Hysterectomy and Laparoscopic Myomectomy: Implications for the Use of Power Morcellation.
Perkins RB; Handal-Orefice R; Hanchate AD; Lin M; Paasche-Orlow MK
Womens Health Issues; 2016; 26(1):21-6. PubMed ID: 26701205
[TBL] [Abstract][Full Text] [Related]
10. Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women.
Lieng M; Berner E; Busund B
J Minim Invasive Gynecol; 2015; 22(3):410-4. PubMed ID: 25460521
[TBL] [Abstract][Full Text] [Related]
11. U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women?
Parker WH; Kaunitz AM; Pritts EA; Olive DL; Chalas E; Clarke-Pearson DL; Berek JS;
Obstet Gynecol; 2016 Jan; 127(1):18-22. PubMed ID: 26646134
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of occult leiomyosarcomas and atypical leiomyomas after laparoscopic morcellation of leiomyomas in reproductive-age women.
Pados G; Tsolakidis D; Theodoulidis V; Makedos A; Zaramboukas T; Tarlatzis B
Hum Reprod; 2017 Oct; 32(10):2036-2041. PubMed ID: 28938732
[TBL] [Abstract][Full Text] [Related]
13. Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroids: an updated decision analysis following the 2014 Food and Drug Administration safety communications.
Siedhoff MT; Doll KM; Clarke-Pearson DL; Rutstein SE
Am J Obstet Gynecol; 2017 Mar; 216(3):259.e1-259.e6. PubMed ID: 27890646
[TBL] [Abstract][Full Text] [Related]
14. The Morcellation Debate: The History and the Science.
Adelman MR
Clin Obstet Gynecol; 2015 Dec; 58(4):710-7. PubMed ID: 26512438
[TBL] [Abstract][Full Text] [Related]
15. Racial Disparities in Response to a US Food and Drug Administration Safety Communication Regarding the Use of Power Morcellation for the Treatment of Uterine Leiomyoma.
Matsushita T; Sekizawa A; Jacobs LK
J Minim Invasive Gynecol; 2020 Jan; 27(1):178-185.e1. PubMed ID: 30936031
[TBL] [Abstract][Full Text] [Related]
16. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.
Raine-Bennett T; Tucker LY; Zaritsky E; Littell RD; Palen T; Neugebauer R; Axtell A; Schultze PM; Kronbach DW; Embry-Schubert J; Sundang A; Bischoff K; Compton-Phillips AL; Lentz SE
Obstet Gynecol; 2016 Jan; 127(1):29-39. PubMed ID: 26646120
[TBL] [Abstract][Full Text] [Related]
17. Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation.
Multinu F; Casarin J; Hanson KT; Angioni S; Mariani A; Habermann EB; Laughlin-Tommaso SK
JAMA Surg; 2018 Jun; 153(6):e180141. PubMed ID: 29641835
[TBL] [Abstract][Full Text] [Related]
18. A medical-legal review of power morcellation in the face of the recent FDA warning and litigation.
Ton R; Kilic GS; Phelps JY
J Minim Invasive Gynecol; 2015; 22(4):564-72. PubMed ID: 25623369
[TBL] [Abstract][Full Text] [Related]
19. FDA warns against power morcellation for hysterectomy and fibroids.
Wallis L
Am J Nurs; 2014 Jul; 114(7):16. PubMed ID: 25742335
[No Abstract] [Full Text] [Related]
20. Minilaparotomy Versus Laparoscopic Myomectomy After Cessation of Power Morcellation: Rate of Wound Complications.
Dubin AK; Wei J; Sullivan S; Udaltsova N; Zaritsky E; Yamamoto MP
J Minim Invasive Gynecol; 2017; 24(6):946-953. PubMed ID: 28552622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
